PEMBROKE PARK, Fla. — A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.
The Food and Drug Administration cleared the test to replace PET scans and spinal fluid tests as the first stop for symptomatic patients 55 and older.
Christine Burger, a volunteer at The Alzheimer’s Association’s Southeast Florida Chapter, celebrated the diagnostic advancement.
“This test can help me know right away if I am going to develop Alzheimer’s or dementia,” Burger said.
Alzheimer’s patients also have two new treatments to slow the progression: Leqembi and Kisunla, IV infusions that help clear the brain plaque.
Burger, who is at risk for Alzheimer’s, said the test results could help her have access to medications early and that is very hopeful.
Copyright 2025 by WPLG Local10.com - All rights reserved.
